Please ensure Javascript is enabled for purposes of website accessibility

Tilray Drops Nearly 6% in After-Hours Trading Following Q1 Report

By Eric Volkman - May 12, 2020 at 11:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cannabis company managed to narrow its net loss on a quarter-over-quarter basis, but that loss was still considerable.

Shares of Tilray (TLRY) were trading down in after-hours action on Monday, following the release of the Canadian marijuana company's first-quarter results after market close.

Tilray booked $52.1 million in revenue for the quarter, 11% more than the preceding quarter's result, and 126% higher on a year-over-year basis. On the bottom line, it booked a net loss of $184 million ($1.73 per diluted share), an improvement over the preceding quarter's $219 million but a much deeper loss than Q1 2019's $29 million.

Medical marijuana with pipe.

Image source: Getty Images.

Revenue was higher than analysts' average estimate of just over $50.6 million. However, those forecasters collectively predicted a net loss of only $0.42 for the period.

Tilray achieved year-over-year sales growth in all of its product categories, in some cases at dramatic rates. Revenue from its core recreational marijuana business rose by 165% to slightly more than $20.9 million. More robust growth came from hemp sales; these climbed almost 300% to $21.3 million (although this was due to a fuller consolidation of its hemp business, Manitoba International, during the quarter).

Revenue in its international medical marijuana segment leaped 221% to $5.8 million, and Tilray is bullish about the future of that market. "As evidenced by our International Medical sales in the quarter, we expect this segment to demonstrate continued growth and positively impact margins," the company wrote in its earnings release.

But investors appeared dismayed by the latest in a string of quarterly losses for the company. Tilray shares were down by almost 6% after hours in the wake of its earnings release late Monday. As of 11:40 a.m. EDT Tuesday, they had recovered somewhat, but remained down by about 3%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.